ERNA
No price yet
Announcements
Nothing here yet
Daily updates
- Ernexa presented non-clinical ERNA-101 data showing robust immune infiltration, tumor reduction, and sustained efficacy in ovarian cancer models, with stronger effects when combined with PD-1 inhibition.Oct 6, 2026
- Ernexa Therapeutics will present preclinical findings for ERNA-101 and its iMSC platform at the 2026 Cell & Gene Meeting on the Mesa, including complete tumor elimination with PD-1 inhibition in ovarian cancer models.Sep 30, 2026
FDA designations
Nothing here yet
News
- Ernexa Therapeutics reported positive preclinical disease-modifying data for ERNA-201, supporting its iMSC platform as the company advances its oncology strategy and ERNA-101 toward first-in-human dosingSep 15, 2026
- Ernexa Therapeutics received independent validation of ERNA-101 showing complete tumor clearance in ovarian cancer modelsJul 15, 2026
- Ernexa Therapeutics unveiled preclinical results showing 100% survival and complete tumor elimination with ERNA-101 in ovarian cancer modelsMay 6, 2026
- Ernexa Therapeutics reports successful pre-IND FDA meeting and continued progress toward first-in-human ovarian cancer trialJan 6, 2026
- Cellipont Bioservices and Ernexa Therapeutics enter cell therapy manufacturing partnership to advance ERNA-101 toward clinical trials in ovarian cancerOct 29, 2025